{"id":"t-cell-infusion-dose-level-1","_chembl":null,"_fixedAt":"2026-03-30T12:16:27.856174","modality":"Biologic","_dailymed":null,"mechanism":{"explanation":"The therapy involves administering T-cells, which are immune cells that can recognize and attack specific targets. Dose Level -1 represents a de-escalated dose tier, typically used in Phase 1 trials when standard starting doses show toxicity concerns.","oneSentence":"Infusion of T-cells to enhance immune response against disease targets."},"_scrapedAt":"2026-03-28T04:46:54.891Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123031,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"tisagenlecleucel","brand":"Kymriah","company":"Novartis","rationale":"CAR-T cell therapy for cancer treatment"},{"name":"axicabtagene ciloleucel","brand":"Yescarta","company":"Gilead/Kite","rationale":"CAR-T cell therapy for hematologic malignancies"}],"description":"T-Cell Infusion Dose Level -1 is an investigational cellular immunotherapy being developed by Baylor College of Medicine. This Phase 1 therapy involves infusion of modified or selected T-cells, representing the lowest dose level in early-stage clinical testing to evaluate safety and tolerability.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"_fixedFields":["pubmed(11)"],"trialDetails":[{"nctId":"NCT05702853","phase":"PHASE1, PHASE2","title":"Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2023-11-06","conditions":"B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia","enrollment":27},{"nctId":"NCT03686124","phase":"PHASE1, PHASE2","title":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2019-05-14","conditions":"Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult","enrollment":375},{"nctId":"NCT06413498","phase":"PHASE3","title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2024-08-23","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT06154252","phase":"PHASE2, PHASE3","title":"RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2023-12-20","conditions":"Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome","enrollment":74},{"nctId":"NCT07489287","phase":"PHASE1","title":"GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-06-15","conditions":"Platinum-resistant Ovarian Cancer","enrollment":18},{"nctId":"NCT01306019","phase":"PHASE1, PHASE2","title":"Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-09-25","conditions":"X-linked Severe Combined Immunodeficiency (XSCID)","enrollment":40},{"nctId":"NCT02830724","phase":"PHASE1, PHASE2","title":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-06","conditions":"Pancreatic Cancer, Renal Cell Cancer, Breast Cancer","enrollment":124},{"nctId":"NCT03721068","phase":"PHASE1","title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-02-19","conditions":"Neuroblastoma, Osteosarcoma","enrollment":18},{"nctId":"NCT07388563","phase":"PHASE1","title":"Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":20},{"nctId":"NCT06904066","phase":"PHASE1","title":"Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic","enrollment":86},{"nctId":"NCT05463133","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":"Chronic Granulomatous Disease","enrollment":50},{"nctId":"NCT07328503","phase":"PHASE2","title":"CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Acute Lymphoblastic Leukemia, B-All","enrollment":20},{"nctId":"NCT07493044","phase":"PHASE1","title":"An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Guangzhou FineImmune Biotechnology Co., LTD.","startDate":"2026-03-20","conditions":"Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT07493395","phase":"PHASE2","title":"Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-04-01","conditions":"Scleroderma, Systemic","enrollment":6},{"nctId":"NCT03533816","phase":"PHASE1","title":"Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2020-01-31","conditions":"Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":38},{"nctId":"NCT07492888","phase":"PHASE2","title":"Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04-15","conditions":"Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis","enrollment":20},{"nctId":"NCT07491263","phase":"PHASE1","title":"Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2026-05-01","conditions":"Relapsed/Refractory CD19-positive B-ALL","enrollment":6},{"nctId":"NCT02315612","phase":"PHASE1","title":"Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":"NHL, Large Cell Lymphoma, Follicular Lymphoma","enrollment":134},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT02133196","phase":"PHASE2","title":"T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-23","conditions":"Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC","enrollment":85},{"nctId":"NCT03412877","phase":"PHASE2","title":"Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-06","conditions":"Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer","enrollment":285},{"nctId":"NCT05003895","phase":"PHASE1","title":"GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-08","conditions":"Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma","enrollment":38},{"nctId":"NCT07200102","phase":"PHASE1","title":"Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-17","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT07380984","phase":"PHASE2","title":"PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03","conditions":"Natural Killer/T-cell Lymphoma","enrollment":47},{"nctId":"NCT07101328","phase":"PHASE1","title":"A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 )","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-06","conditions":"Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":215},{"nctId":"NCT03180216","phase":"PHASE1","title":"T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's National Research Institute","startDate":"2017-02-15","conditions":"Viral Infections, Bone Marrow Transplant Infection","enrollment":32},{"nctId":"NCT07350863","phase":"PHASE1","title":"U69-CART-Cells For R/R T-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-25","conditions":"Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma","enrollment":12},{"nctId":"NCT02789228","phase":"PHASE1","title":"Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's National Research Institute","startDate":"2016-10-12","conditions":"Solid Tumors","enrollment":28},{"nctId":"NCT03745326","phase":"PHASE1, PHASE2","title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-16","conditions":"Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer","enrollment":5},{"nctId":"NCT07481721","phase":"PHASE1","title":"IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma","status":"NOT_YET_RECRUITING","sponsor":"Ming Yang","startDate":"2026-05-01","conditions":"Recurrent Malignant Glioma","enrollment":24},{"nctId":"NCT06375993","phase":"PHASE1","title":"A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Adicet Therapeutics","startDate":"2024-11-10","conditions":"Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc)","enrollment":180},{"nctId":"NCT06708455","phase":"PHASE2","title":"Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Rapa Therapeutics LLC","startDate":"2027-03-01","conditions":"Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc","enrollment":65},{"nctId":"NCT02601313","phase":"PHASE2","title":"Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-11-09","conditions":"Relapsed/Refractory Mantle Cell Lymphoma","enrollment":105},{"nctId":"NCT03070392","phase":"PHASE2","title":"Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma","status":"COMPLETED","sponsor":"Immunocore Ltd","startDate":"2017-10-16","conditions":"Uveal Melanoma","enrollment":378},{"nctId":"NCT07476014","phase":"EARLY_PHASE1","title":"Early Clinical Study on the Use of Donor-derived EBV-specific T Cells for the Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-28","conditions":"Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":18},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT07476326","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Biocon Biologics UK PLC","startDate":"2026-06-01","conditions":"Melanoma","enrollment":120},{"nctId":"NCT06865664","phase":"PHASE1","title":"FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-09-22","conditions":"Rhabdomyosarcoma","enrollment":50},{"nctId":"NCT06026319","phase":"PHASE1","title":"CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2023-10-26","conditions":"Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":24},{"nctId":"NCT07061574","phase":"PHASE1, PHASE2","title":"A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-30","conditions":"Type 1 Diabetes, New Onset","enrollment":120},{"nctId":"NCT07038447","phase":"PHASE1","title":"A Study of KITE-363 in Participants With Refractory Autoimmune Diseases","status":"ENROLLING_BY_INVITATION","sponsor":"Kite, A Gilead Company","startDate":"2025-07-02","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis","enrollment":52},{"nctId":"NCT06561425","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Galapagos NV","startDate":"2022-03-09","conditions":"Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell","enrollment":130},{"nctId":"NCT05783596","phase":"PHASE2","title":"Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Reid Merryman, MD","startDate":"2023-07-18","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma","enrollment":47},{"nctId":"NCT05011422","phase":"PHASE1","title":"Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-11-03","conditions":"Pediatric Hematologic Malignancies","enrollment":50},{"nctId":"NCT06186401","phase":"PHASE1","title":"Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells","status":"RECRUITING","sponsor":"Hideho Okada, MD, PhD","startDate":"2024-04-30","conditions":"EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma","enrollment":20},{"nctId":"NCT04181827","phase":"PHASE3","title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-12","conditions":"Multiple Myeloma","enrollment":419},{"nctId":"NCT05022849","phase":"PHASE1","title":"A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-28","conditions":"Prostatic Neoplasms","enrollment":15},{"nctId":"NCT06875063","phase":"PHASE1","title":"GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2026-04-30","conditions":"Non-hodgkin Lymphoma, Refractory Lymphoma, Chimeric Antigen Receptor T-cell","enrollment":45},{"nctId":"NCT05767359","phase":"PHASE2","title":"CAR- PRISM (PRecision Intervention Smoldering Myeloma)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-04-19","conditions":"Multiple Myeloma, Smoldering Multiple Myeloma","enrollment":20},{"nctId":"NCT07284433","phase":"PHASE1, PHASE2","title":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","status":"RECRUITING","sponsor":"AvenCell Therapeutics, Inc.","startDate":"2026-01-06","conditions":"Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse","enrollment":178},{"nctId":"NCT05442515","phase":"PHASE1, PHASE2","title":"CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-28","conditions":"B-NHL, B-Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia","enrollment":126},{"nctId":"NCT05238792","phase":"PHASE1","title":"Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2021-11-17","conditions":"Solid Tumor","enrollment":36},{"nctId":"NCT06256484","phase":"PHASE1","title":"A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Atara Biotherapeutics","startDate":"2024-09-06","conditions":"Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","enrollment":1},{"nctId":"NCT06185751","phase":"PHASE1","title":"Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-08-22","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT07464951","phase":"PHASE1","title":"CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2026-04-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":30},{"nctId":"NCT07461181","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-30","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":10},{"nctId":"NCT05748197","phase":"PHASE1","title":"A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT07304154","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases","status":"NOT_YET_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2026-03","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis","enrollment":52},{"nctId":"NCT07340853","phase":"PHASE1","title":"CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Thomas Martin, MD","startDate":"2026-02-28","conditions":"Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT07257419","phase":"PHASE1","title":"CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03-03","conditions":"Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy","enrollment":60},{"nctId":"NCT02737046","phase":"PHASE2","title":"Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2016-12-12","conditions":"Adult T-cell Leukemia-Lymphoma, ATLL","enrollment":15},{"nctId":"NCT07000149","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-28","conditions":"Advanced Clear Cell Renal Cell Carcinoma","enrollment":1116},{"nctId":"NCT06326021","phase":"PHASE1","title":"Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2024-04-02","conditions":"Refractory/Relapsed Acute Myeloid Leukaemia","enrollment":27},{"nctId":"NCT05514132","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-23","conditions":"Advanced Solid Tumours","enrollment":14},{"nctId":"NCT06308978","phase":"PHASE1","title":"A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease","status":"RECRUITING","sponsor":"Fate Therapeutics","startDate":"2024-03-28","conditions":"Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc)","enrollment":244},{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT06254326","phase":"PHASE1","title":"ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2024-09-19","conditions":"Recurrent Oligodendroglioma, Progressive Oligodendroglioma","enrollment":12},{"nctId":"NCT06063317","phase":"PHASE1","title":"A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2023-10-02","conditions":"Solid Tumor, Adult","enrollment":25},{"nctId":"NCT04221542","phase":"PHASE1","title":"Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Amgen","startDate":"2020-03-04","conditions":"Prostate Cancer","enrollment":479},{"nctId":"NCT05877599","phase":"PHASE1","title":"A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-07-12","conditions":"Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma","enrollment":46},{"nctId":"NCT05032820","phase":"PHASE2","title":"Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2022-01-05","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT04713046","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-18","conditions":"HPV 16+ Recurrent or Metastatic Cancer","enrollment":24},{"nctId":"NCT03070327","phase":"PHASE1","title":"BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-02-27","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT07297160","phase":"PHASE1","title":"CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-06","conditions":"Lymphoma, Myeloma, Solid Tumors","enrollment":88},{"nctId":"NCT03601078","phase":"PHASE2","title":"An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-12-13","conditions":"Multiple Myeloma","enrollment":312},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT06897930","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-21","conditions":"Lupus Erythematosus, Systemic","enrollment":150},{"nctId":"NCT05361395","phase":"PHASE1","title":"First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-08-24","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":184},{"nctId":"NCT07444281","phase":"PHASE1","title":"An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai AbelZeta Ltd.","startDate":"2024-12-25","conditions":"Squamous Cell Lung Cancer","enrollment":24},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT06364423","phase":"PHASE1, PHASE2","title":"Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-03","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia","enrollment":132},{"nctId":"NCT05870917","phase":"PHASE2","title":"A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-04-25","conditions":"Plasma Cell Leukemia","enrollment":20},{"nctId":"NCT07443020","phase":"PHASE1","title":"Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors","status":"NOT_YET_RECRUITING","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2026-03","conditions":"Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant","enrollment":10},{"nctId":"NCT05319314","phase":"PHASE1","title":"GCC19CART for Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Lyell Immunopharma, Inc.","startDate":"2022-08-01","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT06239220","phase":"PHASE2","title":"PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC","status":"RECRUITING","sponsor":"Glenn J. Hanna","startDate":"2024-02-16","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer","enrollment":25},{"nctId":"NCT03434769","phase":"PHASE1","title":"AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Benjamin Tomlinson","startDate":"2018-07-09","conditions":"Non-Hodgkin Lymphoma","enrollment":31},{"nctId":"NCT05414032","phase":"PHASE2","title":"Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-07-12","conditions":"Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)","enrollment":102},{"nctId":"NCT07416682","phase":"EARLY_PHASE1","title":"CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2026-01-31","conditions":"High-risk Plasma Cell Neoplasms","enrollment":20},{"nctId":"NCT03602612","phase":"PHASE1","title":"T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-14","conditions":"Myeloma-Multiple, Myeloma, Plasma-Cell","enrollment":35},{"nctId":"NCT02291848","phase":"PHASE1","title":"Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-04","conditions":"Multiple Myeloma","enrollment":36},{"nctId":"NCT07434284","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study of cCTL in Combination With Immunotherapy for Advanced Gynecologic Malignancies","status":"RECRUITING","sponsor":"Obstetrics & Gynecology Hospital of Fudan University","startDate":"2026-02","conditions":"Advanced Gynecological Cancers","enrollment":20},{"nctId":"NCT06626919","phase":"PHASE1","title":"A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases","status":"RECRUITING","sponsor":"Arcellx, Inc.","startDate":"2025-04-30","conditions":"Muscular Diseases, Neuromuscular Manifestations, Autoimmune","enrollment":30},{"nctId":"NCT04471727","phase":"PHASE1, PHASE2","title":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2020-12-14","conditions":"Small-Cell Lung Cancer, Neuroendocrine Carcinoma","enrollment":232},{"nctId":"NCT06996782","phase":"PHASE1, PHASE2","title":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":152},{"nctId":"NCT06252402","phase":"EARLY_PHASE1","title":"CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-12-19","conditions":"HIV-1","enrollment":15},{"nctId":"NCT06121297","phase":"PHASE1, PHASE2","title":"RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2024-02-16","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis","enrollment":28},{"nctId":"NCT04186520","phase":"PHASE1, PHASE2","title":"CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2020-05-18","conditions":"Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL)","enrollment":100},{"nctId":"NCT05990465","phase":"PHASE1","title":"LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-02-06","conditions":"Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma","enrollment":12},{"nctId":"NCT02744287","phase":"PHASE1","title":"Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-11-30","conditions":"Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"recentPublications":[{"date":"2026 Feb 4","pmid":"41636724","title":"A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.","journal":"Blood"},{"date":"2025 Jan","pmid":"39617017","title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.","journal":"The Lancet. Oncology"},{"date":"2023 Aug 19","pmid":"37295445","title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.","journal":"Lancet (London, England)"},{"date":"2023 Feb","pmid":"36754451","title":"Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.","journal":"Journal for immunotherapy of cancer"},{"date":"2022 Mar","pmid":"35130560","title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.","journal":"Nature"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"T-Cell Infusion Dose Level -1","genericName":"T-Cell Infusion Dose Level -1","companyName":"Baylor College of Medicine","companyId":"baylor-college-of-medicine","firstApprovalDate":"","aiSummary":"There is no information provided about T-Cell Infusion Dose Level -1. However, based on the given facts, T-Cell Infusion is being studied in various conditions including Rhabdomyosarcoma, Gastrointestinal Tumors, Leukemia, Multiple Myeloma, and Sickle Cell Disease.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}